Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265184 | 1.00 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CYP11B1 | |
| SCHEMBL14578642 | 1.00 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CYP11B1 | |
| SCHEMBL16363077 | 0.76 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CYP11B1 | |
| SCHEMBL13845052 | 0.76 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CXCR2 | |
| SCHEMBL12900509 | 0.76 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CXCR2 | |
| SCHEMBL16363090 | 0.76 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CYP11B1 | |
| SCHEMBL4234627 | 0.76 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CXCR2 | |
| SCHEMBL7508090 | 0.76 | CYP19A1 (0.42) | CYP19A1TBXAS1GID4CCR6CYP11B1 | |
| SCHEMBL20721207 | 0.69 | CCR6 (0.40) | CYP19A1TBXAS1GID4CCR6 | |
| SCHEMBL6101683 | 0.69 | GID4 (0.37) | CYP19A1TBXAS1GID4POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | CYP19A1 671/4885TBXAS1 1299/4885GID4 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.